Compare Lam Research Corporation (LRCX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lam Research Corporation vs GeneDx Holdings Corp — how do they compare? Lam Research Corporation trades at $320.89 (market cap $402.68B), while GeneDx Holdings Corp trades at $62.68 (market cap $1.83B). The key difference: Lam Research Corporation is far larger — about 220× GeneDx Holdings Corp's market cap, and Lam Research Corporation pays a 0.32% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| LRCX | WGS | |
|---|---|---|
Market Cap | $402.68B | $1.83B |
Sector | Technology | Technology |
52-Week High | $433.33 | $167.51 |
52-Week Low | $94.84 | $34.51 |
Enterprise Value | $401.67B | $1.83B |
Dividend Yield | 0.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lam Research (LRCX) trades at $322.00, up 2.78% today, with a bullish technical signal despite mixed moving averages. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $1.47 surpassing the $1.36 forecast. Revenue grew to $18.44B in 2025, and net income margin improved to 30.94%. Analysts maintain a strong buy consensus with a $396.06 price target, though high valuation multiples like a P/E of 57.99 and sector volatility present risks.
Outlook remains positive driven by AI-related semiconductor demand and operational efficiency, but investors face risks from elevated valuations and industry cyclicality. The stock's proximity to the $319 resistance level suggests near-term momentum could hinge on Q2 2026 earnings results against a $1.69 EPS expectation.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
